This is a two-center, open-label, randomized controlled pilot trial with 2-arm parallel group design (1:1 ratio).<h4>Participants</h4>Patients with COVID-19 aged 18-75 with increased Interleukin (IL)-6 levels will be enrolled, but patients with severe infections requiring intensive care will be excluded. The gene discussed is IL6; the disease is infection.